Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems
Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 4
Abstract
In comparison to classical medicines, gene therapy has the potential to mediate the highest possible level of therapeutic specificity. Every normal or diseased cell can switch on or off a gene expression cassette in a tissue-, disease-, and time-dependent fashion, by use of specific transcription factors that are active only in a given unique situation. In practice, we face the problem in realizing the concept: the delivery of nucleic acids into target cells is very ineffective and presents a formidable challenge. Key issues for future developments include improved targeting, enhanced intracellular uptake, and reduced toxicity of gene vectors. The currently used classes of vectors have complementary characteristics, such as high intracellular efficiency of viral vectors on the one hand and low immunogenicity and greater flexibility of nonviral vectors on the other hand. The merge of viral and nonviral vector technologies is highlighted as an encouraging strategy for the future; concepts include chemically modified viral vectors (“chemo-viruses”) and synthesis of virus-like systems (“synthetic viruses”). Examples for the development of vectors toward artificial synthetic viruses are presented.
Authors and Affiliations
Sabine Boeckle, Ernst Wagner
Keywords
Related Articles
- EP ID EP681830
- DOI 10.1208/aapsj080483
- Views 65
- Downloads 0
Comparison of Neutralizing Antibody Assays for Receptor Binding and Enzyme Activity of the Enzyme Replacement Therapeutic Naglazyme® (Galsulfase)
Most patients receiving Naglazyme® (galsulfase, rhASB) enzyme replacement therapy for mucopolysaccharidosis type VI develop an antibody response. To evaluate the impact of this response, two in vitro neutralizing...
Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates
The online version of this article (doi:10.1208/s12248-013-9475-5) contains supplementary material, which is available to authorized users.
Nanomedicine Drug Development: A Scientific Symposium Entitled “Charting a Roadmap to Commercialization”
The use of nanotechnology in medicine holds great promise for revolutionizing a variety of therapies. The past decade witnessed dramatic advancements in scientific research in nanomedicines, although significant challeng...
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
The development of therapeutic proteins requires the understanding of the relationship between the dose, exposure, efficacy, and toxicity of these molecules. Several intrinsic and extrinsic factors contribute to the chal...
UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof